This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
The reverse termination fee in a 2026 strategic deal has quietly become something more specific than the slide-deck version suggests. The headline number — eight percent of equity value is roughly market on a mid-cap deal, somewhat lower on the largest deals, sometimes higher in regulated industries — looks like a flat liquidated-damages figure. Negotiation focuses on the percentage. Bankers report it back as high or low. The buyer’s lawyer says it is market. The seller’s banker says it is generous. And the seller signs without quite realizing that the headline percentage is not the term that does the work.
The terms that do the work are the trigger list and the efforts standard. The reverse termination fee is no longer just compensation for a busted deal. In strategic transactions that face meaningful antitrust risk, the fee has become the buyer’s antitrust co-pay — the price the buyer pays to walk away from a deal the regulators have blocked, the cap on the buyer’s downside exposure if the antitrust commitment in the merger agreement turns out to be more demanding than the buyer modeled at signing. The number that looks generous against one trigger structure can look quite stingy against another. The question is not how big the fee is. The question is what triggers it, what the buyer has to do in the interval between signing and the antitrust drop-dead date to earn the right to walk, and what the seller is signing up to absorb if the buyer walks.
Treating the reverse termination fee as a flat liquidated-damages figure misses the structural shift that has taken place in strategic deal architecture over the last four years, and missing the structural shift is how sellers’ counsel are signing the antitrust risk onto the seller without realizing it. This post lays out where the fee actually sits in the modern deal, what the 2024-2026 strategic deal data shows about how it is being negotiated, and the three drafting moves a seller should be making before signing.
What a reverse termination fee is, and what it isn’t
A reverse termination fee is the amount the buyer agrees to pay the seller if the deal terminates for specified reasons attributable to the buyer. Mechanically, it is the mirror image of the seller-side termination fee that lets the seller walk into a superior proposal. Functionally, it is a hedging instrument: the seller is being paid for the risk that the buyer does not close. The fee is the cap on the seller’s monetary remedy if the buyer walks for a reason the parties allocated to the buyer at signing — most commonly, financing failure (in financed deals) and antitrust failure (in strategic deals where regulatory clearance is the gating item).
The fee is also a signaling device. A buyer who agrees to a substantial reverse termination fee is committing capital to the deal in a way that an LOI cannot. The fee tells the seller that the buyer believes in the deal enough to put a percentage of equity value behind it. In an auction process the size of the fee is one of the variables a sophisticated banker grades the bids against, alongside price, financing certainty, and timing.
What the fee is not — and what 2026 practice has made clearer — is a substitute for the underlying obligation to close. The DGCL merger provisions at 8 Del. C. §§ 251 et seq. contemplate that a buyer’s specific-performance obligation under a merger agreement is a real remedy. The Channel Medsystems line of Chancery cases has reinforced that a buyer cannot simply pay the fee and walk in the absence of a clean termination right. But the reverse termination fee is the cap on the buyer’s monetary liability when the termination right is clean, and the architecture of the termination rights is where the antitrust risk gets allocated.
The 2026 shift
For most of the 2010s, antitrust risk in strategic deals was treated as a binary that the parties resolved at signing. Either the deal was clearable in the regulators’ eyes, in which case the parties agreed to use reasonable best efforts to obtain clearance and the buyer bore meaningful but bounded risk if clearance did not come; or the deal was not clearable, in which case the parties did not sign it. The reverse termination fee in a typical strategic deal was four to six percent of equity value, and it was triggered by a small number of buyer-side failures.
That picture broke in two ways over the last several years. First, the regulators got more active, and the timeline to clearance lengthened. The 2023 HSR reform extended what diligent counsel will tell a client to budget for clearance — twelve to eighteen months in a contested deal, sometimes longer if a second request lands and a Part 803 production has to happen. Second, the universe of “contested” deals expanded. Healthcare, technology, defense, semiconductors — sectors where strategic M&A had historically run on faster timelines — are now sectors where buyers and sellers plan for a long path. The Lattice Semiconductor combinations in 2025 and 2026 are not unusual; they are typical of how semiconductor consolidation now plays out, with public 8-Ks announcing definitive agreements and antitrust timelines that stretch the calendar.
The longer the path to clearance, the more pricing variance the seller is exposed to. A target whose business changes during a twelve-to-eighteen-month interregnum is a target whose equityholders are sitting through a lot of risk for a deal that has not closed. The reverse termination fee in 2026 strategic deals has been re-priced as a co-pay against that risk, not as a fixed liquidated damages number. The fees have grown, but more importantly the trigger architecture has gotten more specific. The fee now usually has separate sub-fees keyed to different termination scenarios. A buyer-financing failure (rare in strategic deals) triggers one number. An antitrust failure triggers a different — and typically larger — number. A buyer breach unrelated to antitrust or financing triggers a third number, often the highest. The “best efforts” obligations attached to antitrust clearance have grown thicker and more prescriptive. The “drop-dead date” — the outside date by which clearance must be obtained or either party can walk — has been pulled apart into multiple dates, with different extension mechanics.
What the architecture actually looks like
A reasonably well-drafted 2026 strategic-deal merger agreement, in a sector with material antitrust risk, has a termination-fee schedule that looks roughly like this. The buyer pays one fee if the deal terminates because of antitrust failure — a failure to clear by the outside date, or a regulator’s injunction, or a buyer’s refusal to commit to a divestiture that the agreement obligated the buyer to commit to. That fee is typically eight to twelve percent of equity value in 2026, with twelve percent being aggressive and ten percent being a common landing point in genuinely risky deals. The buyer pays a different, lower fee if the deal terminates because financing fell apart (uncommon in strategic deals but contemplated). The buyer pays a third, higher fee if the deal terminates because the buyer breached an obligation unrelated to antitrust or financing — for example, a willful refusal to close.
Around those fee numbers, the agreement has an architecture of best-efforts obligations attached to antitrust clearance. The standard “reasonable best efforts” language is still common but increasingly hollowed out by specific carve-outs. The buyer agrees to commit to divestitures up to a “burden cap” — usually expressed as a maximum revenue or asset value of businesses the buyer is required to divest. The buyer agrees to litigate against regulatory challenges for a specified period if challenged. The buyer agrees not to enter into acquisitions in adjacent markets during the interim period that would worsen the antitrust analysis. Each of these obligations has a corresponding fee consequence if breached.
The drop-dead date is no longer a single date. It is a primary outside date, with one or two automatic extensions if antitrust clearance is the only unsatisfied condition. Each extension carries its own mechanics — sometimes a “ticking fee” payable by the buyer to the seller for the duration of the extension, sometimes a reduction in the reverse termination fee, sometimes neither.
Where sellers’ counsel should push
The negotiation should be specific. A seller who signs a 2026 strategic-deal merger agreement with a single reverse termination fee number triggered by a single termination scenario is signing a 2018 agreement, and the buyer’s antitrust risk is being allocated to the seller in ways the seller may not have priced.
First, the fee should be sub-divided by trigger. Antitrust failure deserves a separate, larger number than the catch-all “buyer breach” fee, because antitrust failure is the most likely failure mode in a 2026 strategic deal and the seller is the party most exposed to it.
Second, the best-efforts package should be quantified. The burden cap — the maximum value of businesses the buyer is required to divest — should be set explicitly, in dollars or in revenue. A buyer who agrees to “reasonable best efforts” without a burden cap is a buyer who has reserved the right to argue, twelve months in, that no divestiture is reasonable. The burden cap takes that argument off the table.
Third, the drop-dead architecture should align with realistic antitrust timelines. A nine-month outside date with no extension in a deal that any antitrust lawyer would predict needs fifteen months is a structural setup for a fight over whether the buyer’s efforts were sufficient when clearance did not come on time. The seller should push for an automatic extension keyed to whether the antitrust process is making progress, not a discretionary one.
Fourth, the ticking fee — a per-day or per-month payment by the buyer to the seller during the antitrust interregnum — should be in the conversation. Ticking fees are not standard in every deal, but they are increasingly common in long-timeline deals, and they re-align the buyer’s incentives to move the antitrust process quickly. Standard template language often omits this entirely, and adding it requires deliberate drafting work.
The buyer-side defense
Buyers’ counsel push back on the sub-divided fee architecture for two reasons that are worth taking seriously. The first is that a high antitrust-failure fee creates an incentive for sellers to negotiate antitrust-related conditions hard at signing, knowing that the buyer is exposed if clearance does not come. The second is that a high fee creates a perverse incentive for the seller’s lawyer to be slow at the regulator-response stage, knowing that delay benefits the seller. Neither argument is dispositive, but both are real.
The architecture that resolves both is one where the antitrust fee is meaningful but tied to specific buyer-side failures rather than to the bare fact of non-clearance. A fee triggered by “the buyer’s failure to commit to required divestitures up to the burden cap” is a different animal than a fee triggered by “the failure of the merger to obtain antitrust clearance by the outside date.” The first allocates the risk of buyer behavior; the second allocates the risk of regulator behavior. Sellers should push for the second; buyers should push for the first; the negotiation lands somewhere in between, and the landing place determines who is bearing what.
What this means for the LOI
The LOI is where the seller’s leverage is highest. A seller who signs an LOI with a percentage of equity value listed as the “reverse termination fee” and nothing else has not negotiated. The right LOI language commits the buyer to a sub-divided fee structure, a burden cap with a floor, a ticking-fee mechanism, and an outside date with an automatic extension keyed to antitrust progress. Each of those terms gets papered up in the definitive agreement, but the framework has to be in the LOI. The M&A practice we run sees the same pattern repeatedly: sellers who treat the LOI as a price-and-structure document and not a risk-allocation document end up bearing antitrust risk they did not price.
The reverse termination fee is not a flat number anymore. In strategic deals in 2026 it is a co-pay against the most likely failure mode of the transaction, and the architecture of the co-pay matters as much as its size. Sellers’ counsel who read the fee in isolation are reading the wrong page. The pages that matter are the trigger schedule, the best-efforts package, and the drop-dead architecture. Get those right and the headline number is doing what it is supposed to do. Get them wrong and the headline number is misleading the seller about how much risk the deal is actually shifting to the buyer.
If you are a founder, controlling stockholder, or general counsel negotiating a strategic-deal merger agreement with material antitrust exposure, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
— John
